{"id":8364,"date":"2022-04-18T14:13:00","date_gmt":"2022-04-18T14:13:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3727616_AE27616_0"},"modified":"2022-04-18T14:13:00","modified_gmt":"2022-04-18T14:13:00","slug":"novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=8364","title":{"rendered":"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases"},"content":{"rendered":"<div id=\"dvContent\" readability=\"92.58852192745\">\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1506866\/Novavax_High_Res_Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress<\/i><\/li>\n<li><i>Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax&#8217; COVID-19 vaccine<\/i><\/li>\n<\/ul>\n<p><span class=\"xn-location\">GAITHERSBURG, Md.<\/span>, <span class=\"xn-chron\">April 18, 2022<\/span> \/PRNewswire\/ &#8212; Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3507542-1&amp;h=1840594479&amp;u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-washington%2Findex.stm&amp;a=World+Vaccine+Congress\" target=\"_blank\" rel=\"nofollow noopener\">World Vaccine Congress<\/a> (WVC) in <span class=\"xn-location\">Washington, DC<\/span>, <span class=\"xn-chron\">April 18 &#8211; 21, 2022<\/span>. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373,&nbsp;will be presented at both WVC and the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3507542-1&amp;h=1505958255&amp;u=https%3A%2F%2Fwww.eccmid.org%2F&amp;a=32nd+European+Congress+of+Clinical+Microbiology+%26+Infectious+Diseases\" target=\"_blank\" rel=\"nofollow noopener\">32nd European Congress of Clinical Microbiology &amp; Infectious Diseases<\/a> (ECCMID) in in <span class=\"xn-location\">Lisbon, Portugal<\/span>, <span class=\"xn-chron\">April 23 &#8211; 26, 2022<\/span>. Data from eight abstracts and presentations, including four oral presentations, will be presented across the two congresses.<\/p>\n<p><span class=\"xn-person\">Gregory M. Glenn<\/span>, M.D., President, Research and Development, Novavax, said: &#8220;Our presence at these two leading industry conferences shows our ongoing commitment to addressing COVID-19, and the advances we have made towards a next-generation influenza vaccine. We look forward to sharing these updates that further demonstrate the potential for our platform.&#8221;<\/p>\n<p><b><u>Key Novavax presentations during WVC:<\/u><\/b><\/p>\n<div>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" class=\"prnbcc\">\n<tbody readability=\"10.5\">\n<tr readability=\"7.5\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Glenn, G<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">How long will our immunity <br \/>against COVID-19 last for <br \/>and will our vaccines <br \/>continue to work against <br \/>VoCs?<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Panel<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 19, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">8:45 \u2013 9:45 ET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"6\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Kim, D<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Monitoring COVID-19 Vaccine <br \/>Safety under Emergency Use <br \/>Authorization: Challenges and <br \/>Lessons?<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Panel<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 20, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">12:10 \u2013 1:10 ET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"7\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Glenn, G<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Clinical Update on Novavax&#8217;s <br \/>Recombinant Nanoparticle Protein <br \/>Subunit COVID-19 Vaccine as a <br \/>Booster<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session COVID &amp; Beyond \u2013 M4<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 20, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">12:40 \u2013 12:00 ET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"7\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Shinde, V<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Update on Novavax&#8217; NanoFlu* <br \/>vaccine and COVID-19-Influenza <br \/>Combination Vaccine development<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session Influenza and Respiratory \u2013 M4<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 20, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">12:40 \u2013 1:10 ET<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>*NanoFlu&nbsp;identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.<\/p>\n<p><b><u>Key Novavax presentations during ECCMID:<\/u><\/b><\/p>\n<div>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" class=\"prnbcc\">\n<tbody readability=\"27\">\n<tr readability=\"8\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Toback, S<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Ongoing safety and efficacy <br \/>of the NVX-CoV2373 COVID-19 <br \/>vaccine in the United Kingdom<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract #04525<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session Late breaking updates on COVID vaccination<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 25, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">16:15 \u2013 17:15 CET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"11\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Shinde, V<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"7\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Long-term durability of <br \/>antigen-specific polyfunctional <br \/>CD4+ T cell responses against <br \/>vaccine-homologous and <br \/>antigenically drifted viruses: <br \/>results of a phase III trial <br \/>of a recombinant quadrivalent <br \/>hemagglutinin saponin-adjuvanted <br \/>nanoparticle influenza<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract #1197<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Oral<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session Viral respiratory infections: Influenza and RSV<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 26, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">11:00 \u2013 12:00 CET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"15.5\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">\u00c1\u00f1ez, G<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"7\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Safety, efficacy and effectiveness <br \/>of a SARS-CoV-2 adjuvanted <br \/>recombinant spike protein <br \/>vaccine (NVX-CoV2373) <br \/>in a phase III trial in <br \/>adolescents (PREVENT-19)<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract #04455<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session 12g. Vaccine development, trials, efficacy, policy<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 25, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">12:00 \u2013 13:00 CET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"14\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">\u00c1\u00f1ez, G<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"7\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Molecular epidemiology of SARS-CoV-2 <br \/>strains identified during a phase III, <br \/>efficacy and safety trial of <br \/>NVX-CoV2373 vaccine <br \/>(PREVENT-19) in the <br \/>United States and Mexico<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"7\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract #00284<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session 12l. Virus evolution, variants, and impact<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 25, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">12:00 \u2013 13:00 CET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"14\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Beyhaghi, H<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Reported pregnancies and <br \/>associated outcomes across <br \/>the NVX-CoV2373 COVID-19 <br \/>vaccine clinical development <br \/>programme<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract #01705<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session 12g. Vaccine development, trials, efficacy, policy<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 25, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">12:00 \u2013 13:00 CET<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"12.5\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Marchese, A<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">COVID-19 vaccine receptivity <br \/>and preferences among <br \/>&#8220;vaccine hesitants&#8221;<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"8\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Abstract #04362<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Poster<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Session 12g. Vaccine development, trials, efficacy, policy<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">April 25, 2022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">12:00 \u2013 13:00 CET<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>For more information or to register, visit the&nbsp;<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3507542-1&amp;h=3395465361&amp;u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-washington%2Findex.stm&amp;a=World+Vaccine+Congress+Washington+2022\" target=\"_blank\" rel=\"nofollow noopener\">World Vaccine Congress Washington 2022<\/a> and the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3507542-1&amp;h=1505958255&amp;u=https%3A%2F%2Fwww.eccmid.org%2F&amp;a=32nd+European+Congress+of+Clinical+Microbiology+%26+Infectious+Diseases\" target=\"_blank\" rel=\"nofollow noopener\">32nd European Congress of Clinical Microbiology &amp; Infectious Diseases<\/a> websites.<\/p>\n<p><b>About Novavax&nbsp;<br \/><\/b>Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company&#8217;s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company&#8217;s COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1\/2 clinical trial, which combines NVX-CoV2373 and its quadrivalent influenza investigational vaccine candidate, previously referred to as NanoFlu. These vaccine candidates incorporate Novavax&#8217; proprietary saponin-based Matrix-M\u2122 adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.<\/p>\n<p>For more information, visit&nbsp;<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3507542-1&amp;h=120407650&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3460980-1%26h%3D3623927874%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3457869-1%2526h%253D982408174%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3440781-1%252526h%25253D3964594936%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3395501-1%25252526h%2525253D2463599076%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3392093-1%2525252526h%252525253D203886192%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3387216-1%252525252526h%25252525253D3917401194%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3260461-1%25252525252526h%2525252525253D2897486098%25252525252526u%2525252525253Dhttp%252525252525253A%252525252525252F%252525252525252Fwww.novavax.com%252525252525252F%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&amp;a=www.novavax.com\" target=\"_blank\" rel=\"nofollow noopener\">www.novavax.com<\/a>&nbsp;and connect with us on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3507542-1&amp;h=467528979&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3460980-1%26h%3D91088807%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3457869-1%2526h%253D1725473980%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3440781-1%252526h%25253D2733326919%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3395501-1%25252526h%2525253D853375093%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3392093-1%2525252526h%252525253D1325598136%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3387216-1%252525252526h%25252525253D2935962557%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3260461-1%25252525252526h%2525252525253D1508558197%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3158017-1%2525252525252526h%252525252525253D3702938248%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fwww.linkedin.com%25252525252525252Fcompany%25252525252525252Fnovavax%25252525252525252F%2525252525252526a%252525252525253DLinkedIn%25252525252526a%2525252525253DLinkedIn%252525252526a%25252525253DLinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%252526a%25253DLinkedIn%2526a%253DLinkedIn%26a%3DLinkedIn&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>,.<\/p>\n<p><b>Contacts:&nbsp;<br \/><\/b><u>Investors<br \/><\/u><span class=\"xn-person\">Erika Schultz<\/span> | 240-268-2022&nbsp;<br \/><a href=\"mailto:ir@novavax.com\" target=\"_blank\" rel=\"nofollow noopener\">ir@novavax.com<\/a><\/p>\n<p><u>Media<br \/><\/u><span class=\"xn-person\">Ali Chartan<\/span> | 240-720-7804&nbsp;<br \/><span class=\"xn-person\">Laura Keenan Lindsey<\/span> | 202-709-7521&nbsp;<br \/><a href=\"mailto:media@novavax.com\" target=\"_blank\" rel=\"nofollow noopener\">media@novavax.com<\/a><\/p>\n<\/p><\/div>\n<p>Source: Novavax, Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax&#8217; COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 \/PRNewswire\/ &#8212; Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":8365,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-8364","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=8364\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases - My Blog\" \/>\n<meta property=\"og:description\" content=\"New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax&#8217; COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 \/PRNewswire\/ &#8212; Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=8364\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-18T14:13:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"599\" \/>\n\t<meta property=\"og:image:height\" content=\"264\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases\",\"datePublished\":\"2022-04-18T14:13:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364\"},\"wordCount\":733,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364\",\"name\":\"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg\",\"datePublished\":\"2022-04-18T14:13:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg\",\"width\":599,\"height\":264},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=8364#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=8364","og_locale":"en_US","og_type":"article","og_title":"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases - My Blog","og_description":"New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax&#8217; COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 \/PRNewswire\/ &#8212; Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=8364","og_site_name":"My Blog","article_published_time":"2022-04-18T14:13:00+00:00","og_image":[{"width":599,"height":264,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg","type":"image\/jpeg"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=8364#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=8364"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases","datePublished":"2022-04-18T14:13:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=8364"},"wordCount":733,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=8364#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=8364","url":"https:\/\/transmediavictoria.net.au\/?p=8364","name":"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=8364#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=8364#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg","datePublished":"2022-04-18T14:13:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=8364#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=8364"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=8364#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology-infectious-diseases.jpg","width":599,"height":264},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=8364#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology &amp; Infectious Diseases"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/8364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8364"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/8364\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/8365"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}